NEW YORK, NY--(Marketwired - March 09, 2015) - Plandaí Biotechnology (PLPL) has probably chosen to err on the side of "under promise and over deliver" when it comes to the bioavailability of its green tea extract, Phytofare® Catechin Complex. At least after sitting across the desk from North West University's Professor Anne Grobler, that is the conclusion one could reach regarding what Plandaí has said about its highly bioavailable extract to date.
Professor Grobler, along with her team of scientists at the University, have been conducting human clinical trials on the company's products, and after spending one day with that team, it was clear they are impressed with Phytofare's bioavailability.
Stock Market Media Group, a content development investor relations firm, has written about Plandaí, its technology, and its products for almost two years, and we recently traveled to South Africa with a film crew to document just what it is that the company has built and operates at the Senteeko Tea Estate. Once the corporate video is completed, it will be released to the public. In the meantime, a series of articles will be released to briefly highlight some of what we learned.
First, we landed in the very crowded Johannesburg, before beginning our journey two hours south in Potchefstroom at North West University, home to the largest Pharmacy school in South Africa. The school is ideally set up for drug development, and includes each of the necessary steps in the development pipeline from formulation to stability to preclinical studies to clinical trials. Naturally this is an advantage to any company looking to develop pharmaceuticals or nutraceuticals that will require clinical testing and/or regulatory approval.
Scientists are reserved by nature, but after sitting down with Professor Grobler, her facial expressions and excitement when discussing the clinical trial data for Phytofare told the story that Plandaí's CEO, Roger Duffield, has been telling for years. The company's Phytofare® Catechin Complex was proven to be dramatically more bioavailable than the extract it was compared to in human clinical trials.
We've all heard about the data -- with Phytofare, all 8 of the catechins, which come from the leaves of the green tea plant and provide its health benefits, were present in the bloodstream of those people participating in the trial, versus just two of the plant's catechins found when participants used the commercial extract in the trial. Also, Phytofare provided 5 times greater absorption of those catechins, and the clinical trial found that the life span of the catechin's molecules in the bloodstream was doubled in Phytofare.
This is, of course, the data on paper (http://www.plandaibiotech.com/bioavailability_trial_preliminary_results.pdf), but it's what is not on paper that was exciting to hear from an animated Professor Grobler when she spoke of all eight catechins, which are a sub-class of flavonoids or antioxidant compounds, that her team found in the bloodstream of participants using Phytofare.
"There are functions that the catechins, which were not previously in the blood stream, can now perform. I mean it may be a completely new function that can be supplied by the Plandaí product because previously those molecules were just not absorbed."
Her point was powerful. Because there is no real data available showing all eight of the green tea plant's catechins making it into the bloodstream, she says we could begin to learn about brand new functions that the catechins could carry out in our bodies. When asked about her initial reaction to the results of the study, with a big smile, Professor Grobler said, "I have to do it again." She added that the results were "that dramatic."
Professor Grobler made a point to repeat the importance of what the study really tells us, which is an area that has not been fully highlighted and explains how the company's green tea extract could be more potent than first reported.
"The duration of circulation of those catechins in the blood was increased dramatically in the case of the Plandaí product, and that is important because now you're maintaining a therapeutic level of those molecules in the blood that was previously not possible," said Grobler.
Make no mistake about it, that data alone could hold the key to Plandaí's future with Phytofare. For the end user of the company's green tea extract, the results from this study could be viewed as more beneficial than first reported. The Professor says with the company's product, a user would only need to take one Phtyofare capsule every 24 hours. She explained, "After 24 hours, the level of catechins (in the blood) in the case of the Plandaí product is still higher than the maximum concentration ever obtained from the commercial green tea extract used in the study."
More comments from Professor Grobler and her team will be aired in the corporate video, and in the next article we meet the more than impressive Senteeko Tea Estate.
About Stock Market Media Group
SMMG is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.
Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $3,500 per month by Plandai Biotechnology for content development. Previously, SMMG was compensated for similar content by a third party which occurred from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its content. Neither SMMG nor anyone associated with it owns shares in PLPL. For more information: www.stockmarketmediagroup.com.